The proposed bill mandates that the Arkansas Medicaid Program cover authorized prescription digital therapeutics specifically designed for the treatment of substance and opioid use disorders. It introduces a new section to the Arkansas Code that outlines legislative findings emphasizing the importance of expanding access to innovative, evidence-based treatments to combat the opioid epidemic. The findings highlight the potential benefits of these digital therapeutics, including their ability to save lives and provide a cost-neutral alternative to traditional treatment methods.

The bill defines "authorized prescription digital therapeutic" as a technology approved by the United States Food and Drug Administration that employs cognitive behavioral therapy and contingency management for treating substance use disorders. It stipulates that coverage will be provided to individuals deemed eligible by a licensed provider in the state. This initiative aims to enhance treatment accessibility for citizens facing barriers to traditional care, thereby addressing a critical public health issue in Arkansas.